WM: 2025 update on diagnosis, risk stratification, and management

Key Findings

• ●Recommended first-line: BR or zanubrutinib
• ●Discussed pirtobrutinib, venetoclax, and BTK degraders in relapsed WM
• ●Updated prognostic models and risk stratification

Referenced in (1 disease)